Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Profit After Tax (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Profit After Tax for 10 consecutive years, with -$7.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Profit After Tax rose 56.73% year-over-year to -$7.4 million, compared with a TTM value of -$44.0 million through Sep 2025, down 1337.17%, and an annual FY2024 reading of -$68.6 million, down 400.88% over the prior year.
  • Profit After Tax was -$7.4 million for Q3 2025 at Spero Therapeutics, down from -$1.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $51.2 million in Q4 2023 and bottomed at -$32.8 million in Q1 2022.
  • Average Profit After Tax over 5 years is -$10.8 million, with a median of -$13.9 million recorded in 2025.
  • The sharpest move saw Profit After Tax surged 191.56% in 2022, then plummeted 433.54% in 2024.
  • Year by year, Profit After Tax stood at -$29.2 million in 2021, then soared by 191.56% to $26.8 million in 2022, then skyrocketed by 91.2% to $51.2 million in 2023, then crashed by 140.97% to -$21.0 million in 2024, then surged by 64.71% to -$7.4 million in 2025.
  • Business Quant data shows Profit After Tax for SPRO at -$7.4 million in Q3 2025, -$1.7 million in Q2 2025, and -$13.9 million in Q1 2025.